Showing results (31-40 of 365) with videos related to
Sort By:
Pageof 37
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 8, 2025
Bispecific Antibodies in Hematologic and Solid Tumors: Current Landscape and Therapeutic AdvancesLorenzo Guidi, Julian Etessami, Carmine Valenza, et al.Lung Cancer (Amsterdam, Netherlands)|May 29, 2026
First-line treatment patterns and real-world outcomes in patients with advanced KRAS-mutated non-small cell lung cancer with high unmet needFabrice Barlesi, Ferdinandos Skoulidis, Benjamin Solomon, et al.Journal of Thoracic Disease|April 16, 2013
Bone metastases with nerve root compression as a late complication in patient with epithelial pleural mesotheliomaSusana Cedrés, Lorena Fariñas, Neda Stejpanovic, et al.Journal of Clinical Pharmacology|December 29, 2022
A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid TumorsMichael J Hanley, Manolo D'Arcangelo, Enriqueta Felip, et al.Cancers|May 14, 2025
BAP1 Mutations and Pleural Mesothelioma: Genetic Insights, Clinical Implications, and Therapeutic PerspectivesSusana Cedres, Augusto Valdivia, Ilaria Priano, et al.American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 10, 2023
Antibody-Drug Conjugates for Lung Cancer: Payloads and ProgressSamuel Rosner, Augusto Valdivia, Hui Jing Hoe, et al.The Oncologist|March 21, 2019
Clinical Management of Adverse Events Associated with LorlatinibTodd M Bauer, Enriqueta Felip, Benjamin J Solomon, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 16, 2010
Computed tomography (CT) predicts accurately the pathologic tumour size in stage I non-small-cell lung cancer (NSCLC)Susana Cedrés, Isela Quispe, Pablo Martínez, et al.Advances in Therapy|March 21, 2024
Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature ReviewMustafa Khasraw, Priyanka Yalamanchili, Anu Santhanagopal, et al.Clinical Lung Cancer|May 22, 2012
A phase Ib, dose-finding study of erlotinib in combination with a fixed dose of pertuzumab in patients with advanced non-small-cell lung cancerEnriqueta Felip, Malcolm Ranson, Susana Cedrés, et al.Pageof 37